Genmab News

Jul 31, 2020 at 9:37 PM CEST Genmab Announces European Myeloma Network and Janssen Achieve Positive Topline Results from Phase 3 APOLLO Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma	Download
Jul 20, 2020 at 5:57 PM CEST Major Shareholder Announcement	Download
Jul 16, 2020 at 12:43 PM CEST Genmab Announces Net Sales of DARZALEX® for the Second Quarter of 2020	Download
Jul 7, 2020 at 1:01 PM CEST Major Shareholder Announcement	Download
Jul 3, 2020 at 9:18 PM CEST Major Shareholder Announcement	Download
Jul 3, 2020 at 9:51 AM CEST Major Shareholder Announcement	Download
Jul 1, 2020 at 3:45 PM CEST Genmab A/S has published its Articles of Association	Download
Jun 30, 2020 at 7:52 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise	Download
Jun 29, 2020 at 10:29 PM CEST Genmab Announces Very Favorable Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer	Download
Jun 11, 2020 at 1:53 PM CEST Genmab A/S has published its Articles of Association	Download
Jun 10, 2020 at 12:00 PM CEST Genmab and AbbVie Announce Broad Oncology Collaboration	Download
Jun 4, 2020 at 3:42 PM CEST Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma	Download
Jun 4, 2020 at 2:09 PM CEST Genmab to Participate in a Virtual Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference	Download
Jun 3, 2020 at 9:57 PM CEST Grant of Restricted Stock Units and Warrants to Employees in Genmab	Download
Jun 2, 2020 at 10:36 PM CEST U.S. FDA Extends Review of sBLA, Submitted by Novartis, for Ofatumumab in Relapsing Multiple Sclerosis	Download
May 28, 2020 at 6:14 PM CEST Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis	Download
May 14, 2020 at 3:40 PM CEST Genmab Announces Data to be Presented at the EHA25 Virtual Congress	Download
May 13, 2020 at 5:55 PM CEST Genmab A/S has published its Articles of Association	Download
May 12, 2020 at 7:11 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise	Download
May 6, 2020 at 5:11 PM CEST Genmab Announces Financial Results for the First Quarter of 2020	Download 1.13 MB
May 1, 2020 at 7:36 PM CEST Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma	Download 128.27 KB
Apr 30, 2020 at 8:55 PM CEST CHMP Issues Positive Opinion Recommending Subcutaneous Formulation of Daratumumab for the Treatment of Patients with Multiple Myeloma	Download 124.52 KB
Apr 29, 2020 at 9:04 PM CEST Genmab Announces Data to be Presented at ASCO20 Virtual Scientific Program	Download 109.29 KB
Apr 14, 2020 at 12:35 PM CEST Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2020	Download 119.35 KB
Apr 1, 2020 at 10:19 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	Download

NEWS & EVENTS

Through timely company announcements, media releases, events and presentations, Genmab discloses and informs all our stakeholders of key events throughout the year.

Genmab News

Genmab News

Who we are

Turning insights into medicine

Innovation for the future

Genmab A/S

Genmab B.V.

Genmab US, Inc.

Genmab K.K.

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.